[go: up one dir, main page]

KR910011259A - 뉴모시스토시스 치료 또는 예방에 사용하기 위한 플루오로퀴놀론 유도체로 구성된 약제 - Google Patents

뉴모시스토시스 치료 또는 예방에 사용하기 위한 플루오로퀴놀론 유도체로 구성된 약제 Download PDF

Info

Publication number
KR910011259A
KR910011259A KR1019900020271A KR900020271A KR910011259A KR 910011259 A KR910011259 A KR 910011259A KR 1019900020271 A KR1019900020271 A KR 1019900020271A KR 900020271 A KR900020271 A KR 900020271A KR 910011259 A KR910011259 A KR 910011259A
Authority
KR
South Korea
Prior art keywords
prevention
radical
treatment
atom
pneumocystosis
Prior art date
Application number
KR1019900020271A
Other languages
English (en)
Inventor
로젠하임 미쉘
젠띨리니 마르크
거이오트 앤
Original Assignee
프랑소와즈 로브조와
로오느-푸우랜크 상뜨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프랑소와즈 로브조와, 로오느-푸우랜크 상뜨 filed Critical 프랑소와즈 로브조와
Publication of KR910011259A publication Critical patent/KR910011259A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

뉴모시스토시스 치료 또는 예방에 사용하기 위한 플루오로퀴놀론 유도체로 구성된 약제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 하기 일반식 (I)의 플루오로퀴놀론 또는 그들이 염으로 구성된, 뉴모시스토시스(pneumocystosis)의 예방 또는 치료에 사용하기 위한 약제:
    상기식에서, X는 질소원자 또는 기=CR6-를 나타내고, R1은 C1-C4를 함유한 알킬 라디칼, 플루오로에틸, 시클로프로필 또는 디플루오로페닐 라디칼이거나, R1및 R6이 그들을 연결하는 원자들과 함께, 메탈라디칼로 치환되고 임의로산소원자를 함유한 6-원으로 구성된 헤테로사이클을 형성하고, R2, R3및 R4는 동일하거나 서로 다르며 수소원자 또는 메틸라디칼을 나타내고, R6은 수소 또는 불소원자이거나 전기된 바와 같은 헤테로시 클릭고리의 일부를 형성하고 R5는 수소원자, 또는 만일 R6이 불소원자라면, 수소원자 또는 아미노라디칼이다.
  2. 제1항에 있어서, 페플록삭신 (R1=Et, R2=Me, R3, R4, R5=H,X=CH) 에녹삭신(R1=Et, R2, R3, R4, R5=H, X=N), 노르플록삭신(R1=Et, R2, R3, R4, R5=H, X=CH), 오플로삭신(R1, R2이 화학식의 고리의 부분을 이루고 R2=Me, R3, R4, R5,=H) 스파르플록삭신(R1=시클로프로필, R2=H,R3, R4=Me, R5=N, X=CF) 플레록삭신(R1=2-플루오로에틸, R2=Me, R3, R4, R5=H, X=CF), 로메플록삭신(R1=Et, R2=Me, R3, R4, R5=H, X=CF) 또는 테마플록삭식(R1=2,4-디플루오로페닐, R2, R3=H R4=Me, R5=H, X=CH)또는 전술된 화합 물중 임의의 하나의 염인 약제.
  3. 제2항에 있어서, 페플록삭신(R1=Et,R2=Me, R3, R4, R5=H, X=CH) 오플록삭식(R1, R2이 화학식의 고리의 부분을 이루고, R2=Me, R3, R4, R5=H) 또는 테마플록삭신(R1=2,4-디플루오로페닐, R2,R3=H,R4=Me,R5=H,X=CH) 또는 전술된 화합물중 임의의 하나의 염인 약제.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, 동물의 예방 또는 치료에 사용하기 위한 약제.
  5. 제1항에 청구된 바와같은 화합물 및 제약학적으로 허용가능한 회석제 또는 담체로 구성된 제약학적 조성물로 구성된, 뉴모시스토시스의 예방 또는 치료에 사용하기 위한 약제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900020271A 1989-12-11 1990-12-10 뉴모시스토시스 치료 또는 예방에 사용하기 위한 플루오로퀴놀론 유도체로 구성된 약제 KR910011259A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8916324 1989-12-11
FR8916324A FR2655545B1 (fr) 1989-12-11 1989-12-11 Nouvelle application therapeutique des derives des fluoroquinolones.

Publications (1)

Publication Number Publication Date
KR910011259A true KR910011259A (ko) 1991-08-07

Family

ID=9388344

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900020271A KR910011259A (ko) 1989-12-11 1990-12-10 뉴모시스토시스 치료 또는 예방에 사용하기 위한 플루오로퀴놀론 유도체로 구성된 약제

Country Status (16)

Country Link
US (1) US5179096A (ko)
EP (1) EP0437128B1 (ko)
JP (1) JPH03251532A (ko)
KR (1) KR910011259A (ko)
AT (1) ATE101518T1 (ko)
AU (1) AU626743B2 (ko)
CA (1) CA2031886A1 (ko)
DE (1) DE69006707T2 (ko)
DK (1) DK0437128T3 (ko)
ES (1) ES2062464T3 (ko)
FR (1) FR2655545B1 (ko)
HU (1) HU207947B (ko)
IE (1) IE64720B1 (ko)
IL (1) IL96618A (ko)
PT (1) PT96164B (ko)
ZA (1) ZA909886B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT67395A (en) * 1993-07-13 1995-04-28 Somfai Method for the n-cyclopropylation of primary and secondary aromatic amines
US5906962A (en) * 1994-12-22 1999-05-25 Rhodia Inc. Non-aqueous suspension concentrates of highly water-soluble solids
US5707551A (en) * 1994-12-22 1998-01-13 Rhone-Poulenc Inc. Nonaqueous suspension concentrates of highly water-soluble solids
US6024979A (en) * 1995-06-06 2000-02-15 Solvay Animal Health, Inc. Oral veterinary composition containing a fluoroquinolone antibacterial agent possessing superior absorption properties and an extended duration of therapeutic antimicrobial blood levels, and a method of treating a microbial infection in a ruminant
US5686095A (en) * 1995-10-23 1997-11-11 Price, Jr.; Francis W. Method of treating canker sores
KR100459747B1 (ko) * 1996-05-20 2005-01-27 오쓰까 세이야꾸 가부시키가이샤 로제시아치료제
JPH10143977A (ja) 1996-09-10 1998-05-29 Sony Corp ディスク装置およびそれを用いたビデオカメラ装置
IN186245B (ko) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6060474A (en) * 1998-11-05 2000-05-09 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for preventing scar tissue formation
US6346391B1 (en) 1999-07-22 2002-02-12 Trustees Of Tufts College Methods of reducing microbial resistance to drugs
BRPI0407368A (pt) * 2003-02-10 2006-02-14 Bayer Healthcare Ag tratamento de doenças bacterianas dos órgãos respiratórios mediante aplicação local e fluor-quinolonas.
EP2056709A4 (en) * 2006-08-11 2013-05-01 Univ New Jersey Med DOUBLE-SENSITIZER WITH LUMINESCENCE COMPOUNDS, CONJUGATES AND USE
WO2011088193A2 (en) 2010-01-13 2011-07-21 University Of Medicine And Dentistry Of New Jersey Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1175836A (en) * 1977-09-20 1984-10-09 Marcel Pesson Production of 1,4-dihydroquinoline-3-carboxylic acid derivatives
GB1598915A (en) * 1977-09-20 1981-09-23 Bellon Labor Sa Roger 1,4-dihydro-quinoline-3-carboxylic acid derivatives process for their preparation and composition containing them
JPS5845426B2 (ja) * 1978-09-29 1983-10-08 杏林製薬株式会社 置換キノリンカルボン酸誘導体
JPS5630964A (en) * 1979-08-22 1981-03-28 Kyorin Pharmaceut Co Ltd Novel substituted quinolinecarboxylic acid and its preparation
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4620007A (en) * 1980-09-03 1986-10-28 Bayer Aktiengesellschaft 6-fluoro-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
DE3142854A1 (de) 1981-10-29 1983-05-11 Bayer Ag, 5090 Leverkusen 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7-piperazino-chinolin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
SE440354B (sv) * 1981-02-19 1985-07-29 Kyorin Seiyaku Kk Kinolinkarboxylsyraderivat
NZ208470A (en) * 1983-07-18 1988-06-30 Abbott Lab 6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid derivatives and antibacterial compositions containing such
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
AU553415B2 (en) * 1983-09-19 1986-07-17 Abbott Japan Co., Ltd. 6-fluoro-1-4-dihydro-4-oxo-7-substituted piperazinyl- quinoline-3-carboxylic acids
US4551456A (en) * 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
DE3577089D1 (de) * 1984-01-26 1990-05-17 Abbott Lab Antibakterielle chinolinderivate.
US4774246A (en) * 1984-01-26 1988-09-27 Abbott Laboratories Quinoline antibacterial compounds
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
NO166131C (no) * 1985-06-20 1991-06-05 Daiichi Seiyaku Co Analogifremgangsmaate for fremstilling av s(-)-pyridobenzoksazinforbindelser.
DE3608745A1 (de) * 1985-07-24 1987-01-29 Bayer Ag Bakterizide zubereitungen zur anwendung auf dem gebiet der veterinaermedizin
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
AU594983B2 (en) 1985-10-29 1990-03-22 Dainippon Pharmaceutical Co. Ltd. Novel quinoline derivatives and processes for preparation thereof
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
DE3632222A1 (de) * 1986-09-23 1988-04-07 Bayer Ag Topisch anwendbare zubereitungen von gyrase-inhibitoren
DE3637649A1 (de) * 1986-10-13 1988-04-14 Uwe Dr Spohr Verwendung von 4-chinolon-derivaten zur bekaempfung von protozoen und helminthen
DE3704907A1 (de) * 1987-02-17 1988-08-25 Bayer Ag Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
IT1231425B (it) * 1987-10-05 1991-12-04 Prodotti Antibiotici Spa Procedimento per la sintesi di un derivato dell'acido benzo (ij) chinolizin-2-carbossilico
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
US4978661A (en) * 1988-09-29 1990-12-18 Innocenzo Caruso Use of 6-halo-4-quinolone compounds and pharmaceutical compositions thereof for the preparation of a medicament for the therapeutical application in rheumatoid arthritis

Also Published As

Publication number Publication date
EP0437128B1 (fr) 1994-02-16
IE904449A1 (en) 1991-06-19
DE69006707D1 (de) 1994-03-24
DK0437128T3 (da) 1994-03-14
ES2062464T3 (es) 1994-12-16
HUT55991A (en) 1991-07-29
ATE101518T1 (de) 1994-03-15
PT96164B (pt) 1998-04-30
JPH03251532A (ja) 1991-11-11
ZA909886B (en) 1991-09-25
HU908146D0 (en) 1991-06-28
IL96618A (en) 1995-05-26
HU207947B (en) 1993-07-28
AU626743B2 (en) 1992-08-06
US5179096A (en) 1993-01-12
CA2031886A1 (fr) 1991-06-12
IE64720B1 (en) 1995-08-23
AU6786290A (en) 1991-06-13
EP0437128A2 (fr) 1991-07-17
IL96618A0 (en) 1991-09-16
FR2655545A1 (fr) 1991-06-14
EP0437128A3 (en) 1992-09-30
DE69006707T2 (de) 1994-06-09
PT96164A (pt) 1991-09-30
FR2655545B1 (fr) 1994-06-10

Similar Documents

Publication Publication Date Title
DE69230163D1 (de) Thiazolylbenzofuranderivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
DE69021472D1 (de) Pyrazolderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellung.
KR910011259A (ko) 뉴모시스토시스 치료 또는 예방에 사용하기 위한 플루오로퀴놀론 유도체로 구성된 약제
YU109991A (sh) Aralifatske n-substituisane aminoalkanfosfinske kiseline i postupak za njihovo pripremanje
HUP9801356A2 (hu) Triciklusos (2-hidroxi-2-metil-3,3,3-trifluor-propanoil)-amino-benzoxepin-, -benzotiepin-, -benzocikloheptén-, -indén-származékok és az ezeket tartalmazó gyógyszerkészítmények
NO304379B1 (no) 11,21-bisfenyl-19-norpregnan-derivater, anvendelse derav og farmas°ytiske preparater inneholdende slike derivater
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
ATE78470T1 (de) Imidazolin-derivate und verfahren zu deren herstellung.
ATE48001T1 (de) Cephemverbindungen, verfahren zu ihrer herstellung und ihre pharmazeutischen praeparate.
DK425487A (da) Pharmaceutisk aktive derivater af glutamin- og asparginsyre
KR880012586A (ko) 새로운 피리딜 및 피리미딜 유도체
DE69315836D1 (de) Pyrazolpyridine für die behandlung der anämie
ES528462A0 (es) Procedimiento de preparacion de nuevos derivados dialquilaminoalcoxibencilalcoholicos y de sus sales de adicion acidas y amonicas cuaternarias
NO852514L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 8-alkyltio-2-piperazino-pyrimido (5,4-d) pyrimidin-derivater.
NO913023D0 (no) Nye bicykliske aminosubstituerte forbindelsr.
ATE68494T1 (de) Benzofuranderivate und diese enthaltende therapeutische mittel.
ATE5480T1 (de) Thiazolo(3,2-a)pyrimidinderivate, ihre herstellung und arzneimittel, die diese derivate enthalten.
ATE3549T1 (de) Theophyllin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
KR950702540A (ko) 치료법에 사용하기 위한 피라미딘 화합물(pyrimidine compounds used in the therapy)
ES476232A1 (es) Procedimiento para la obtencion de derivados del fosfonilu- reidobenceno.
IT1261958B (it) 2-(sostituite immino)-tiazolidine e procedimento per la loro preparazione e loro impiego quali antianginose e/o analgesiche
RU94038051A (ru) Гетероциклические производные, способ их получения, фармацевтическая композиция и способ лечения
PE20030438A1 (es) Medicamento que comprende un derivado de eritromicina como agente antituberculoso
TH51868A (th) อนุพันธ์อะมิโนเฟนิลพิริมิโดน
TH9283A (th) สารต่อต้านแบคทีเรียชนิด 5-ซับสทิทวเทด-1,4-ไดไฮโดร-4-ออกโซ-แนฟไอริดีน-3-คาร์บอนซิเลท

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19901210

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid